FRCPC

MCI Onehealth and Oro Health Collaborate to Launch New Teledermatology Platform

Retrieved on: 
Wednesday, September 21, 2022
Health, Dermatology, Precision medicine, Time, Gaps, TSX, Efficiency, Prescription, Nature, Intention, Compliance, Industry, FRCPC, Environment, Forward-looking statement, Patient, Clinical trial, Phrase, Risk, Physician, CEO, Technology, MCI, Solution, Bachelor of Science, Diagnosis, Telephone, Research, GLOBE, SEDAR, Pharmaceutical industry, Hospital, Medicine, Accessibility for Ontarians with Disabilities Act, 2005, COVID-19

This collaboration with Oro Health expands our convenient virtual care offering and accelerates access to specialty care, said Dr. Alexander Dobranowski, CEO of MCI.

Key Points: 
  • This collaboration with Oro Health expands our convenient virtual care offering and accelerates access to specialty care, said Dr. Alexander Dobranowski, CEO of MCI.
  • The innovative platform utilizes Oro Health technology that employs dynamic intelligent triage, facilitating swift categorization and assessment of a patients dermatological condition.
  • We are excited to collaborate with MCI Onehealth and provide our technology to enable a new teledermatology online consultation service for Ontario-based patients awaiting faster and broader access to dermatological care, said Dr. Emilie Bourgeault, CEO of Oro Health, BSc., M.D., Dermatologist (FRCPC).
  • MCI is already a leader in the virtual/telehealth care sector with 300,000 annual patient visits via telephone or MCIs general health virtual platform, MCI Connect.

Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo Nordisk, Joining the Board of Directors and Heather Turner, J.D. Joining as COO

Retrieved on: 
Wednesday, September 21, 2022
Biotechnology, General Health, Diabetes, Health, Pharmaceutical, Lists of diseases, Therapy, General counsel, State Bar of California, Philosopher's stone, Law, MD, Novo, University, Director, Senior, Acquisition, Compliance, GSK, Obesity, FRCPC, Program, COO, Cooley LLP, Orexigen Therapeutics, Patient, Cancer, Bar association, IPO, CE, Amgen, Physician, Surgeon, Board of directors, Doctor of Philosophy, Leadership, Novo Nordisk, Board, KRAS, Royal college, Cooley, Drug, Pharmaceutical industry, Lyell

Anne Phillips, MD, FRCPC joins Carmots Board and Heather Turner, J.D., joins as Chief Operating Officer.

Key Points: 
  • Anne Phillips, MD, FRCPC joins Carmots Board and Heather Turner, J.D., joins as Chief Operating Officer.
  • We are delighted to welcome Anne Phillips to our Board, said Stig Hansen, PhD, Carmots co-founder and Chief Executive Officer.
  • "I'm also delighted to have Heather Turner join Carmot as COO and member of our executive leadership team, said Stig Hansen.
  • About Carmot Therapeutics, Inc. Carmot Therapeutics (Carmot) is focused on the discovery and development of disease-modifying therapies for patients living with metabolic diseases and cancer.

AmyriAD to Host a Key Opinion Leader Webinar on Alzheimer’s Disease Management

Retrieved on: 
Monday, September 19, 2022
Fillit, Acetylcholine, LOS, Twitter, AD, Entrepreneurship, EDT, Cornell University, LinkedIn, Cognition, FRCPC, Therapy, EU, Patient, Degenerative disease, Rockefeller University, Biology, McGill University, Donepezil, Cornell University School of Continuing Education and Summer Sessions, Dementia, Palliative care, Clinical, GLOBE, KOL, Icahn School of Medicine at Mount Sinai, Disease, Pharmaceutical industry, Medical device, Neuroscience, Psychiatry, Ageing, Neurology, Medicine

LOS ANGELES, Sept. 19, 2022 (GLOBE NEWSWIRE) -- AmyriAD Therapeutics, a privately held, late clinical-stage pharmaceutical development company focused on advancing therapies for Alzheimer’s disease, today announced that it will host a key opinion leader (KOL) webinar, entitled, “Looking Beyond Amyloid for Alzheimer’s Disease:   Combination Therapy, a Strategy Long Overdue,” to take place virtually on Friday, September 30, 2022 at 11:15 AM Eastern Daylight Time.

Key Points: 
  • However, less attention has been given to developing therapies for effective management of the core symptoms of the disease, which are declining cognition and loss of independent function.
  • Dr. Gauthier will discuss the benefits of add-on therapies for managing the core symptoms of AD.
  • Clinical Trials on Alzheimers Disease Task Force and former Director of the Alzheimer Disease and Related Disorders Research Unit of the McGill Center for Studies in Aging and Douglas Research Centre.
  • AmyriAD is a privately held, late-stage clinical development pharmaceutical company focused on advancing therapies to improve Alzheimers disease and is led by the development strategist who introduced the cognition enhancing medication ARICEPT.

Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022

Retrieved on: 
Saturday, September 10, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, MAPK, Mutation, Cancer, ESMO, Safety, View, Fatigue, Feedback, Hyponatremia, LLC, Neoplasm, Union, RAS, Program, Phosphorylation, RTK, Private Securities Litigation Reform Act, SEC, Appetite, Patient, Dehydration, GIST, COVID-19, Pharmacokinetics, KRAS, BID, Enzyme, Vomiting, MAP, RAF, BRAF, FRCPC, NASDAQ, AUC, Autophagy, Nausea, United Kingdom, ULK, ALT, Alanine transaminase, RECIST, Entrepreneurship, AST, Anemia, LinkedIn, MEK, Pharmaceutical industry, Generic drug, Twitter

As the first ULK1/2 inhibitor to enter clinical development, these positive initial results represent a significant milestone as we prepare to initiate combination dose escalation later this year.

Key Points: 
  • As the first ULK1/2 inhibitor to enter clinical development, these positive initial results represent a significant milestone as we prepare to initiate combination dose escalation later this year.
  • The preliminary data show DCC-3116 to be a very well-tolerated agent that has demonstrated strong target inhibition of ULK 1/2 from even the lowest tested dose.
  • I look forward to the selection of the combination starting dose and advancing the program into the first combination studies with MEK and KRASG12C inhibitors.
  • Deciphera, the Deciphera logo, QINLOCK, and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC.

CanariaBio Announces Milestone achievement of 50% patient enrollment in its Phase III FLORA-5 clinical study of its lead product oregovomab in front-line advanced ovarian cancer treatment

Retrieved on: 
Thursday, June 30, 2022
Death, Patient, Biotechnology, HER2/neu, MUC1, Gynaecology, Trial of the century, Immunization, Cancer, Immunoglobulin G, Terminology, GOG, PSA, Risk, Overalls, Immunotherapy, Toxicity, Antibody, Oregovomab, Survival, Paclitaxel, FRCPC, Leadership, Safety, MH, Carboplatin, Drug combination, Ovarian cancer, Cancer immunology, Pharmaceutical industry

For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.

Key Points: 
  • For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.
  • Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial.
  • Clinical and translational results were published in Gynecology Oncology 2020 156:523-529) and Cancer Immunology and Immunotherapy 2020 69: 383-397, respectively.
  • CanariaBio Inc. is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer.

CanariaBio Announces Milestone achievement of 50% patient enrollment in its Phase III FLORA-5 clinical study of its lead product oregovomab in front-line advanced ovarian cancer treatment

Retrieved on: 
Thursday, June 30, 2022
Death, View, Patient, Biotechnology, HER2/neu, MUC1, Gynaecology, Trial of the century, Immunization, Cancer, Multimedia, Immunoglobulin G, Terminology, GOG, PSA, Risk, Overalls, Immunotherapy, Toxicity, Antibody, Oregovomab, Survival, Paclitaxel, FRCPC, Leadership, Safety, MH, Carboplatin, Drug combination, Ovarian cancer, Cancer immunology, Pharmaceutical industry

For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.

Key Points: 
  • For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.
  • Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial.
  • Clinical and translational results were published in Gynecology Oncology 2020 156:523-529) and Cancer Immunology and Immunotherapy 2020 69: 383-397, respectively.
  • CanariaBio Inc. is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer.

AACC Elects New Leaders to Serve Terms Starting in August 2022

Retrieved on: 
Wednesday, June 15, 2022
ASCP, Pathology, St. Paul's Hospital, Science, University, University of Pittsburgh Medical Center, Leadership, University of Rochester Medical Center, Wilfrid Sellars, MD, Health, Hospital, University of North Carolina School of Law, NRCC, Association, Health equity, AACC, Child, Physician, FRCPC, University of Pittsburgh School of Medicine, Medical college, Medical College of Wisconsin, Doctor of Philosophy, URMC, Knowledge, UPMC, CPP, Mass spectrometry, Toxicology, Chapel Hill, University of California, San Diego, UPMC Children's Hospital of Pittsburgh, Paul the Apostle, MBA, CC, Committee, Point-of-care testing, Head, Awareness, Management, Medical device, Pharmaceutical industry

Following this, she will serve successive terms as the association's president from August 2023-July 2024 and as past president from August 2024-July 2025.

Key Points: 
  • Following this, she will serve successive terms as the association's president from August 2023-July 2024 and as past president from August 2024-July 2025.
  • They will take office in August 2022 along with the incoming president of AACC Academy and the incoming chair of the AACC Clinical Laboratory Scientists Council, both of whom will also serve on the board.
  • "I am elated that AACC's membership has elected me to serve as president-elect of the association," said Dr. Peck Palmer.
  • An AACC member since 2005, he currently serves on the AACC Education Core Committee and as past chair of the AACC Endocrinology Division.

Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022

Retrieved on: 
Monday, June 13, 2022
ENDO, Maintenance, OLE, Lead, Data, Oles, Doctor of Philosophy, Trinity Medical Sciences University, ULN, Growth factor, Nasdaq, Physician, Endocrine system, FACE, Neurosurgery, Patient, OOC, Safety, Oregon Health & Science University, RCT, Overalls, Oregon Health Plan, FRCPC, Degenerative disease, Mayo Clinic, DPC, SRL, Pharmaceutical industry, Acromegaly, Endocrinology, MD

As a practicing endocrinologist, I believe that these data should give physicians more insights into the long-term benefit of Mycapssa for eligible patients.

Key Points: 
  • As a practicing endocrinologist, I believe that these data should give physicians more insights into the long-term benefit of Mycapssa for eligible patients.
  • As the first orally administered SRL approved for appropriate patients, OOC may represent a favorable option for maintenance therapy.
  • The MPOWERED trial was a global, randomized, open-label and active-controlled, 15-month trial intended to support approval of Mycapssa in the European Union.
  • At the end of the RCT phase patients were provided the option to continue into an open label phase and receive Mycapssa.

BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks

Retrieved on: 
Monday, June 6, 2022
Kallikrein, Adult, BioCryst Pharmaceuticals, Time, Food, PARK, CYP3A4, Safety, Abdominal pain, Gastroesophageal reflux disease, Plasma, Plasma kallikrein, Disease, BCRP, Back pain, Digoxin, Rifampicin, Nasdaq, HAE, Hereditary angioedema, GLOBE, Health Canada, Patient, RESEARCH, CYP2D6, Ciclosporin, Berotralstat, MD, Attack, Canada, Vomiting, Diarrhea, FRCPC, Liver, Pharmaceutical industry, Dentistry, QT

We look forward to working with stakeholders across the country to ensure these Canadians can receive timely and appropriate access to ORLADEYO.

Key Points: 
  • We look forward to working with stakeholders across the country to ensure these Canadians can receive timely and appropriate access to ORLADEYO.
  • These reactions generally occurred early after initiation of treatment with ORLADEYO, became less frequent with time and typically self-resolved.
  • ORLADEYO (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older.
  • ORLADEYO (berotralstat)is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

The International Science Reserve Announces Executive Board and Unveils its First Crisis Activation on Wildfire Prevention and Management

Retrieved on: 
Thursday, April 14, 2022
Government, Board of directors, COVID-19, Executive, Research, United Nations, Technology, United States national laboratories, IBM Research, Knowledge, National Science Foundation, Nuffield Department of Population Health, Wildfire, AGAF, Doctor of Philosophy, Anglo-French Wars, International Science Council, Solution, IBM, Division, New York Academy of Sciences, Senior, Nature, Private sector, CEO, Board, NYAS, Climate change, WWII, Master of Science, MD, DARPA, NASA, Department, Population, FRCPC, Professor, UL, Rockefeller Foundation, Chairperson, Exercise, Time, Population health, NYU, Health, HPCC, New York University Grossman School of Medicine, High Performance Computing Modernization Program, ISR, NEW, Federal Executive Boards, Pandemic, Pharmaceutical industry, Management, Uranium, Pfizer, Google, Science

NEW YORK, April 14, 2022 /PRNewswire/ -- The New York Academy of Sciences (NYAS) and its founding members — including Google, IBM, Pfizer, and UL — today announced the official activation of the International Science Reserve (ISR). Recognizing that our world's scientific capacity exists across borders, institutions, and sectors, the ISR brings together global scientists across government, academia, and industries to collaborate across geographies and sectors to prepare for and help mitigate potential global crises – from future pandemics to the consequences of climate change. 

Key Points: 
  • When a crisis of transnational scale and sufficient urgency occurs, the Executive Board mobilizes the ISR.
  • "Science in the time of crisis is rapid, requiring quick decisions, on the basis of limited information,"says President and CEO of NYAS, Nicholas Dirks.
  • "The world needs the International Science Reserve," says IBM Senior Vice President and Director of IBM Research, Daro Gil.
  • In the last two decades, there has been a sharp increase in wildfire season length, wildfire frequency and acreage burned.